ImmunodeficienciesMarch 23, 20265 min read

Comparison table: Complement deficiencies

Quick-hit shareable content for Complement deficiencies. Include visual/mnemonic device + one-liner explanation. System: Immunology.

Complement questions love to look “vague” (recurrent Neisseria, angioedema, lupus-like disease) and then turn into easy points if you can map which arm is broken—classical vs alternative vs terminal vs regulation. This quick-hit guide is designed to be screenshot-friendly for your notes and fast to recall on test day.


The 10-second map: what complement does (and where it breaks)

Think of complement as 3 roads that merge into one highway:

  • Classical pathway (C1, C2, C4): triggered by immune complexes (IgG/IgM)
  • Alternative pathway (Factor D, Factor B, Properdin): triggered by microbial surfaces
  • Lectin pathway (MBL): triggered by mannose

All three converge on C3, then proceed to:

  • C5–C9 (MAC) = membrane attack complex that pokes holes in bacteria (especially Neisseria)

Visual mnemonic (shareable): “4 C’s” + “MAC attack” + “angioedema switch”

1) Early classical: C1, C2, C4 = “C’s for Complexes”

  • Mnemonic: C1/C2/C4 → immune Complexes
  • One-liner: Early classical deficiency causes immune-complex disease (SLE-like) and recurrent pyogenic infections.

2) C3 = “C3 is the Center”

  • Mnemonic: C3 = Central opsonin
  • One-liner: C3 deficiency is the worst: no opsonization → recurrent severe pyogenic infections + type III hypersensitivity.

3) C5–C9 = “MAC attack”

  • Mnemonic: C5–C9 = MAC → Neisseria
  • One-liner: Terminal complement deficiency → recurrent Neisseria (meningitidis/gonorrhoeae).

4) C1 esterase inhibitor = “brake on bradykinin”

  • Mnemonic: C1-INH inhibits kallikrein → ↓ bradykinin
  • One-liner: C1-INH deficiency → hereditary angioedema (no urticaria; ACE inhibitors can worsen).

Comparison table: Complement deficiencies (high-yield)

DeficiencyPathway/FunctionClassic clinical clueOrganisms / associationsLabs (common patterns)USMLE one-liner
C1q, C2, C4Early classical (immune complex clearance)SLE-like disease, recurrent sinopulmonary infectionsEncapsulated pyogenic bacteria (due to impaired opsonization via downstream effects); immune complex disease↓ CH50, normal AH50 (alternative intact)“Early classical = immune complexes → lupus-like + infections.”
C3Central convergence; opsonization (C3b) and amplificationRecurrent severe pyogenic infections, otitis/sinusitis/pneumonia; can have GNEncapsulated bacteria (e.g., Strep pneumo, H. flu), plus immune complex disease↓ CH50, ↓ AH50 (both rely on C3)“C3 is the center—if it’s gone, everything gets worse.”
C5–C9MAC formation (lysis)Recurrent Neisseria infectionsN. meningitidis, N. gonorrhoeae↓ CH50, normal AH50 or can be abnormal depending on assay design; classic teaching: CH50 low, AH50 often low too in terminal defects (both end in MAC)“No MAC → Neisseria keeps coming back.”
Factor DAlternative pathway activationRecurrent respiratory infections; can see Neisseria susceptibilityNeisseria and some pyogenic infectionsNormal CH50, ↓ AH50“Alternative pathway broken → AH50 low.”
Factor BAlternative pathway C3 convertase componentRecurrent infections similar to other alt pathway defectsPyogenic infections; sometimes NeisseriaNormal CH50, ↓ AH50“B for ‘Broken alternative’.”
ProperdinStabilizes alternative C3 convertaseRecurrent Neisseria, fulminant meningococcemiaNeisseria (notably high yield)Normal CH50, ↓ AH50“Properdin props up alternative—without it, Neisseria wins.”
DAF (CD55) ± CD59 (often acquired in PNH)Protects host cells from complement (DAF blocks C3 convertase; CD59 blocks MAC)Intravascular hemolysis, thrombosis (PNH)Not primarily infections; complement-mediated RBC lysisComplement assays variable; flow cytometry: ↓ CD55/CD59“No shield on RBCs → complement punches holes.”
C1 esterase inhibitor (C1-INH)Inhibits complement + kallikrein (↓ bradykinin)Hereditary angioedema: episodic swelling, laryngeal edema, abdominal painNot an infection problemNormal C3, low C4 common; CH50 may be low“Angioedema without hives; treat by blocking bradykinin pathway.”
MBL (mannose-binding lectin)Lectin pathway initiationOften mild; recurrent childhood infectionsPyogenic infections in infants/young childrenCH50/AH50 often normal (lectin not captured well)“Lectin deficiency is usually subtle.”
💡

Test-day note on CH50 vs AH50:

  • CH50 screens the classical → terminal pathway.
  • AH50 screens the alternative → terminal pathway.
  • If both are low, think C3 (or a shared terminal component depending on lab), but the highest-yield pattern is:
    • Early classical defects: ↓ CH50, normal AH50
    • Alternative defects: normal CH50, ↓ AH50
    • C3: both ↓
    • Terminal (C5–C9): classically ↓ CH50; AH50 may also be abnormal since it also requires terminal components—know the clinical clue (Neisseria) first.

Rapid-fire “name that deficiency” (USMLE style)

  • Recurrent Neisseria meningitis in a teenC5–C9 (or properdin if AH50 selectively low)
  • SLE-like disease + recurrent infectionsC1/C2/C4
  • Severe recurrent pyogenic infections starting earlyC3 deficiency
  • Angioedema, abdominal pain, no urticaria; triggered by stress/trauma; worsened by ACE inhibitorC1-INH deficiency
  • Intravascular hemolysis + thrombosis; pancytopeniaPNH (CD55/CD59)

Micro-associations worth memorizing

Encapsulated bacteria love complement defects (especially when opsonization is impaired)

  • Strep pneumoniae
  • H. influenzae
  • Neisseria meningitidis (especially terminal/alternative pathway)

Why: Loss of C3b opsonization (and downstream effects) reduces clearance of encapsulated organisms.


High-yield treatments (when asked)

  • Hereditary angioedema (C1-INH deficiency):
    • Acute: C1-INH concentrate, icatibant (bradykinin B2 antagonist), ecallantide (kallikrein inhibitor)
    • Avoid: ACE inhibitors (increase bradykinin)
  • Terminal complement deficiency:
    • Prevention: meningococcal vaccination + consider prophylactic antibiotics in select cases

Take-home screenshot summary

  • C1/C2/C4SLE-like + infections
  • C3severe pyogenic infections (worst)
  • C5–C9Neisseria
  • Properdin/Factor D/Balternative pathway; Neisseria risk
  • C1-INHangioedema without urticaria
  • CD55/CD59PNH hemolysis